Bristol Myers Squibb (BMY) Cost of Revenue (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Cost of Revenue for 18 consecutive years, with $3.7 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 10.5% year-over-year to $3.7 billion in Q2 2026; TTM through Jun 2026 was $14.7 billion, a 3.56% increase from a year earlier, with the FY2025 full-year figure at $13.9 billion, changed 0.23% from the prior year.
• Cost of Revenue was $3.7 billion for Q2 2026 at Bristol Myers Squibb, up from $3.4 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $4.8 billion in Q4 2024 and troughed at $2.4 billion in Q3 2022.
• A 5-year average of $3.1 billion and a median of $2.9 billion in 2024 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue surged 75.3% in 2024 and declined 14.86% in 2025, its largest moves.
• Over 5 years, Cost of Revenue stood at $2.6 billion in 2022, then climbed by 5.86% to $2.7 billion in 2023, then surged by 75.3% to $4.8 billion in 2024, then slipped by 14.86% to $4.1 billion in 2025, then retreated by 9.06% to $3.7 billion in 2026.
• The last three Cost of Revenue figures came in at $3.7 billion (Q2 2026), $3.4 billion (Q1 2026), and $4.1 billion (Q4 2025), per Business Quant data.